Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.51 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | PARP15 | Q460N3 | 4/20 | 0.46 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.43 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5352876 | 0.87 | SIRT2 (0.48) | PARP10SIRT2MAOBPARP15PARP14 | |
| SCHEMBL5354497 | 0.84 | SIRT2 (0.46) | PARP10SIRT2MAOBNR4A2 | |
| SCHEMBL6803013 | 0.83 | SIRT2 (0.49) | PARP10SIRT2MAOBPARP15NR4A2 | |
| SCHEMBL15709261 | 0.79 | PARP15 (0.60) | PARP10SIRT2MAOBPARP15PARP14 | |
| SCHEMBL5355208 | 0.78 | SIRT2 (0.41) | PARP10SIRT2MAOBPARP15PARP14 | |
| SCHEMBL7372540 | 0.78 | NPC1 (0.47) | PARP10SIRT2MAOBKMT2ASMN1; SMN2 | |
| SCHEMBL4930554 | 0.77 | PARP10 (0.60) | PARP10SIRT2MAOBPARP15NR4A2 | |
| SCHEMBL7370244 | 0.76 | SPHK2 (0.47) | PARP10SIRT2MAOBKMT2A | |
| SCHEMBL3454792 | 0.76 | PARP15 (0.62) | PARP10SIRT2MAOBPARP15NR4A2 | |
| SCHEMBL7907691 | 0.76 | MAOB (0.73) | PARP10SIRT2MAOBPARP15NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253194-B2 | Compounds and inhibitors of phospholipases | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-08-07 | — | — | US | disclosed |
| US-20040033995-A1 | Compounds and inhibitors of phospholipases | QUEENSLAND, THE UNIVERSITY OF (AU) | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040033995-A1 | Compounds and inhibitors of phospholipases | PLA2G4C, PLA2G4B, PLA2G4A | PARP10 2145/4885SIRT2 4701/4885MAOB 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.